1. Do all patients, who are diagnosed with bowel cancer under the age of 50 years in your trust, have a molecular screening test for Lynch Syndrome, such as immunohistochemistry or microsatellite instability testing, carried out on tumour tissue?
2. If yes, at what stage does this testing take place? Does it take place:
☐ Pre treatment i.e. at diagnosis (on a biopsy of the tumour)
ü Post treatment i.e. test is carried out on the tumour resection specimen
3. Is this test carried out as a reflex test i.e. automatically or upon referral?
☐ Referral via MDT
☐ Referral via Genetics Centre
☐ Referral via GP
☐ Other (please explain)
4. Which of the following molecular tests does your trust use to identify people who could have Lynch syndrome:
ü Microsatellite Instability (MSI)
☐ Immunohistochemistry (IHC)
ü BRAF and MLH1
5. Are the results of this reflex test communicated to the patient?
6. If no such reflex test is in place, do you have information on whether there are any plans to introduce molecular testing for Lynch syndrome? N/A